GlassScriptPhysician profile
Amy L Varner
NPI 1992909931
$2,568.34
in general payments reported to CMS, 2019-2025
28 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $56.31 · 2021: $40.81 · 2022: $379 · 2023: $527 · 2024: $689 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,754.42 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $474.11 | 2019-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $380.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $292.08 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $165.58 | 2019-2024 | Krystexxa |
| Inspire Medical Systems, INC. | $137.89 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $134.58 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $112.10 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $95.26 | 2022-2023 | |
| Abbott Laboratories | $92.02 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $86.43 | 2020-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.71 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $80.87 | 2021-2023 | Gardasil 9, M-M-R II, Pneumovax 23 |
| Bayer Healthcare Pharmaceuticals INC. | $64.43 | 2022-2023 | |
| Astellas Pharma US INC | $52.17 | 2025 | Veozah |
| Exact Sciences Corporation | $39.67 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $34.76 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $30.75 | 2019-2024 | Heplisav-B |
| Dexcom, INC. | $25.85 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $24.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $20.98 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.08 | 2022 | |
| Eisai INC. | $17.94 | 2020 | |
| Esperion Therapeutics, INC. | $17.12 | 2024 | Nexletol |
| Supernus Pharmaceuticals, INC. | $15.82 | 2022 | |
| Heartflow, INC. | $15.73 | 2022 | |
| Axogen | $15.06 | 2019 | |
| Horizon Therapeutics Plc | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Varner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.